CardioprotectionDerek Hausenloy, Derek Yellon Coronary heart disease (CHD) is the leading cause of death worldwide with 3.8 million men and 3.4 million women dying each year. Cardioprotection refers to the prevention of CHD and the clinical improvement in patients suffering from cardiovascular problems. This book focuses on the role of cardioprotection in surgery and the use of pharmacological therapies such as ACE-inhibitors, statins and beta-blockers in order to reduce the myocardial injury sustained by the patient and thesignificant risk of morbidity and mortality. It includes new cardioprotective strategies aimed at improving the clinical outcomes of patients in these settings, as well as current well-established methods for reducing myocardial injury in acute coronary syndrome patients. |
Contents
Foreword | |
Symbols and abbreviations | |
Contributors | |
1 An Introduction to Cardioprotection | |
2 Primary Prevention of Coronary Heart Disease | |
3 Percutaneous Coronary Intervention and Thrombolysis in AMI and other ACS | |
4 AntiPlatelet and AntiThrombotic Therapy PostAMI | |
5 Coronary NoReflow and Microvascular Obstruction | |
Other editions - View all
Common terms and phrases
activation acute coronary syndromes acute myocardial infarction addition adenosine adjunctive administration agents aspirin associated benefit blood bone marrow bypass CABG cardiac Cardiol cardioprotection Chapter CHD risk Circulation clinical outcomes clinical studies clopidogrel compared controlled coronary artery coronary heart disease currently damage death demonstrated diabetes early effects elevation et al experimental factors Figure flow fraction function glucose guidelines Hausenloy heart failure heparin IIb/IIIa imaging improve increased infusion inhibition inhibitors intravenous invasive ischaemia ischaemic ischaemic preconditioning Lancet levels limited lower major mechanisms mortality myocardial ischaemia myocardial reperfusion myocardium no-reflow onset patients with acute percutaneous coronary intervention perfusion platelet postconditioning potential PPCI prevention primary protection randomized rates recent receptor reduce reperfusion injury reported risk setting significant ST-elevation ST-segment stem cells STEMI strategies stroke surgery therapy thrombolysis thrombolytic therapy tion treated treatment trial ventricular Yellon